Table 3.
Linear Mixed Effects Model: Estimated Change in Creatinine and Creatinine Clearance Since Start of TDF Treatment, Years 1 vs 2–6
| Unadjusted Estimates | Adjusted Estimatesa | P Value Interactionc | ||||||
|---|---|---|---|---|---|---|---|---|
| Coefficientb | 95% CI | P Value | Coefficientb | 95% CI | P Value | Time × Sex | Time × Cirrhosis | |
| Creatinine, mg/dL (n = 233) | ||||||||
| Average change per month | ||||||||
| Overall (1–75 mo) | 0.000 | .000 to .001 | .144 | 0.000 | −.001 to .001 | .964 | .004 | .092 |
| Men | … | … | … | −0.001 | −.001 to .000 | .127 | … | … |
| Women | … | … | … | 0.001 | .001 to .002 | <.001 | … | … |
| Year 1 (1–12 mo) | 0.011 | .007 to .015 | <.001 | 0.010 | .006 to .014 | <.001 | … | … |
| Years 2–6 (13–75 mo) | −0.001 | −.002 to .000 | .045 | −0.001 | −.002 to −.000 | .006 | … | … |
| Creatinine clearance, mL/min (n = 229)d | ||||||||
| Average change per year | ||||||||
| Overall (1–75 mo) | −0.19 | −.25 to −.12 | <.001 | −0.15 | −.22 to −.09 | <.001 | .215 | .310 |
| Year 1 (1–12 mo) | −1.42 | −1.88 to −.97 | <.001 | −1.38 | −1.84 to −.93 | <.001 | … | … |
| Years 2–6 (13–75 mo) | −0.10 | −1.20 to −.01 | .032 | −0.07 | −.17 to .02 | .143 | … | … |
Interaction with sex and liver cirrhosis is described.
Abbreviations: TDF, tenofovir disoproxil fumarate.
a
Estimates adjusted for decompensated liver cirrhosis, age, and sex.
b
Marginal mean estimates extracted from the linear mixed effects model with random intercept.
c
P value from interaction between time and sex or cirrhosis, included in the overall and adjusted models. Stratified results are presented in case of significant interaction.
d
Four missing values because of missing body weight.